The main risk is sequencing. Stem likely has real product relevance in a growing control-layer niche, but liquidity binds before the strategy fully proves itself. If Q3 and the next few quarters do not show durable bookings, margin quality, and cash stabilization, refinancing terms,
dilution, or customer caution can absorb much of the operating progress before common shareholders benefit.